Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Phytotherapy and NAFLD--from goals and challenges to clinical practice.

Milosević N, Milanović M, Abenavoli L, Milić N.

Rev Recent Clin Trials. 2014;9(3):195-203. Review.

PMID:
25514914
2.

Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.

Yang Z, Zhuang L, Lu Y, Xu Q, Chen X.

Biomed Res Int. 2014;2014:941085. doi: 10.1155/2014/941085. Epub 2014 Aug 27. Review.

3.

Recent advances in the nanotechnology-based drug delivery of Silybin.

Wang Y, Zhang L, Wang Q, Zhang D.

J Biomed Nanotechnol. 2014 Apr;10(4):543-58. Review.

PMID:
24734507
4.

New therapeutic potentials of milk thistle (Silybum marianum).

Milić N, Milosević N, Suvajdzić L, Zarkov M, Abenavoli L.

Nat Prod Commun. 2013 Dec;8(12):1801-10. Review.

PMID:
24555302
5.

Biotransformation of silybin and its congeners.

Křen V, Marhol P, Purchartová K, Gabrielová E, Modrianský M.

Curr Drug Metab. 2013 Dec;14(10):1009-21. Review.

PMID:
24261705
6.

Silymarin and S-adenosyl-L-methionine (SAMe): two promising pharmacological agents in case of chronic alcoholic hepathopathy. A review and a point of view.

Testino G, Leone S, Ansaldi F, Borro P.

Minerva Gastroenterol Dietol. 2013 Dec;59(4):341-56. Review.

PMID:
24212353
7.

Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action.

Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, Dutta Choudhury M, Mohanakumar KP.

CNS Neurosci Ther. 2013 Nov;19(11):847-53. doi: 10.1111/cns.12175. Epub 2013 Oct 14. Review.

PMID:
24118806
8.

Milk thistle: a future potential anti-osteoporotic and fracture healing agent.

Mohd Fozi NF, Mazlan M, Shuid AN, Isa Naina M.

Curr Drug Targets. 2013 Dec;14(14):1659-66. Review.

PMID:
24093748
9.

Complementary and alternative medicine (CAM) in prostate and bladder cancer.

Philippou Y, Hadjipavlou M, Khan S, Rane A.

BJU Int. 2013 Dec;112(8):1073-9. doi: 10.1111/bju.12062. Review.

10.

Advances in prostate cancer chemoprevention: a translational perspective.

Nambiar D, Singh RP.

Nutr Cancer. 2013;65 Suppl 1:12-25. doi: 10.1080/01635581.2013.785006. Review.

PMID:
23682779
11.

Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.

Mateen S, Raina K, Agarwal R.

Nutr Cancer. 2013;65 Suppl 1:3-11. doi: 10.1080/01635581.2013.785004. Review.

12.
13.

Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Ting H, Deep G, Agarwal R.

AAPS J. 2013 Jul;15(3):707-16. doi: 10.1208/s12248-013-9486-2. Epub 2013 Apr 16. Review.

14.

Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B.

Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW.

Eur J Clin Microbiol Infect Dis. 2013 May;32(5):657-69. doi: 10.1007/s10096-012-1789-1. Epub 2012 Dec 18. Review.

PMID:
23247631
15.

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Polyak SJ, Ferenci P, Pawlotsky JM.

Hepatology. 2013 Mar;57(3):1262-71. doi: 10.1002/hep.26179. Review. No abstract available.

16.

Hepatitis C virus and natural compounds: a new antiviral approach?

Calland N, Dubuisson J, Rouillé Y, Séron K.

Viruses. 2012 Oct 17;4(10):2197-217. doi: 10.3390/v4102197. Review.

17.

Hepatitis C viral kinetics: the past, present, and future.

Chatterjee A, Smith PF, Perelson AS.

Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003. Review.

18.

Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.

Hackett ES, Twedt DC, Gustafson DL.

J Vet Intern Med. 2013 Jan-Feb;27(1):10-6. doi: 10.1111/jvim.12002. Epub 2012 Nov 9. Review.

19.

Silymarin for HCV infection.

Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM.

Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25. Review.

20.

Hepatitis C therapy in non-genotype 1 patients: the near future.

Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L.

J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x. Review.

PMID:
22762136

Supplemental Content

Loading ...
Support Center